Eli Lilly's Retatrutide, a next-generation obesity drug, has shown promising results in clinical trials, with participants losing up to 25% of their body weight. This triple-hormone agonist builds on the success of tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy) by targeting GLP-1, GIP, and glucagon receptors. The combination aims to enhance metabolic effects like insulin release, fat breakdown, and appetite suppression. Retatrutide's addition of glucagon may help regulate blood sugar and lipid levels, potentially offering a more comprehensive approach to obesity treatment compared to existing dual-acting therapies.

The drug's mechanism involves complex interactions between three key hormones: GLP-1, produced in the ileum and colon; GIP, secreted by K cells in the small intestine; and glucagon, released from pancreatic alpha cells. While GLP-1 and GIP promote insulin secretion and satiety, glucagon helps mobilize glucose and fatty acids during low blood sugar. Together, they also stimulate adiponectin release, improving insulin sensitivity and reducing inflammation. If approved, Retatrutide could represent a significant advancement in pharmaceutical obesity management.